Clexio Biosciences
Eli Eyal is an experienced biostatistician with a strong background in the pharmaceutical industry. Currently serving as a Biostatistician at Clexio Biosciences since July 2019, Eli previously held the position of Director of Biostatistics at Pluristem Therapeutics from July 2017 to June 2019. Prior to that, Eli was the Chief Biostatistician at Teva Pharmaceuticals for 25 years, from May 1992 to June 2017. Eli Eyal holds an M.Sc in Applied Statistics and a B.Sc in Mathematics and Operations Research, both from Tel Aviv University.
This person is not in any offices
Clexio Biosciences
Clexio Biosciences is a CNS-first clinical-stage pharmaceutical company. Our therapies are designed to address patients’ unmet needs through scientifically based integration of drugs with innovative technologies. Clexio’s growing pipeline is focused on the development of safe and effective treatments with rapid onset of action for a wide range of neurological and psychiatric conditions, including Major Depressive Disorder, Parkinson’s Disease, Pain and other conditions involving impairment of the neurological system. Patients, and what they are living with, are at the center of everything we do. Our passion is to find ways to help patients regain a sense of balance, health and a life worth living. Clexio’s team is comprised of a multi-disciplinary team with vast experience in drug development. We see our team and our partners as the key ingredients to our success. Join our vision to make lives of millions of patients worth living again.